A Two Part Bioequivalence Study to Compare Two Fixed Dose Combination (FDC) Tablets of Dapagliflozin/Metformin XR 5/500 mg (Part 1) and 10/1000 mg (Part 2) Manufactured at Two Different Plants (Humacao, Puerto Rico and Mount Vernon, US) in Healthy Subjects Under Fasting and Fed Conditions
Phase of Trial: Phase I
Latest Information Update: 30 Nov 2017
At a glance
- Drugs Dapagliflozin/metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 27 Nov 2017 Status changed from recruiting to suspended.
- 25 Oct 2017 Planned End Date changed from 16 Nov 2017 to 30 Jan 2018.
- 25 Oct 2017 Planned primary completion date changed from 16 Nov 2017 to 30 Jan 2018.